Azetukalner data show significant reductions in seizure frequency across weekly, monthly and multi-year time points X-TOLE2 data featured in Late-breaking Science session show 53.2% reduction in monthly seizure frequency in 25 mg group vs. 10.4% for placebo and increasing rates of 100% seizure reduction over time during 12-week double-blind period Long-term data from the ongoing X-TOLE OLE study at 48 months show nearly 40% of participants achieving at least 12 months of seizure freedom and one in four participants achieving at least 24 months of seizure freedom Real-world data reinforce the value of anti-seizure medications that do not require titration to reduce stress and simplify focal seizure management for both patients and physiciansVANCOUVER, British Columbia and BOSTON, MA, April 19, 2026 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals...

KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma OS benefit observed across key subgroups, including patients with high tumor burden, elevated LDH, and extrahepatic disease as well as those with best response of progressive disease This is the longest OS follow-up in a randomized trial in metastatic uveal melanoma and for any T cell engager in a solid tumor (OXFORDSHIRE, England & GAITHERSBURG, Md., & RADNOR, Penn., US, 19 April 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that KIMMTRAK® (tebentafusp-tebn)...

REDWOOD CITY, Calif., April 19, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated Phase 1 (RMC-9805-001) clinical data for zoldonrasib, an oral RAS(ON) G12D-selective inhibitor, in patients with previously treated KRAS G12D non-small cell lung cancer (NSCLC). Results were highlighted in the official press program at the American Association for Cancer Research (AACR) Annual Meeting and will be featured in a plenary oral presentation today, April 19, 2026, at 1:30 p.m. PDT. “Patients with RAS G12D non-small cell lung cancer remain a population with a significant unmet medical need for targeted therapeutic options,” said Jonathan Riess M.D., medical director of thoracic oncology at UC...

MP0632 nominated as first logic-gated Switch-DARPin T cell engager candidate for the treatment of MSLN/EpCAM expressing solid tumors, with preclinical data indicating favorable therapeutic window MP0712, Radio-DARPin candidate in on-going US Phase 1/2a trial, leverages high affinity to DLL3, half-life extension and DLL3 internalization for high tumor accumulationZURICH-SCHLIEREN, Switzerland and CONCORD, Mass, April 19, 2026 (GLOBE NEWSWIRE) — Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the presentation of new preclinical data across three posters at the American Association for Cancer Research (AACR) Annual Meeting 2026. The first poster outlines preclinical...

Schneider ElectricSchneider Electric at Hannover Messe 2026HANNOVER, Germany, April 19, 2026 (GLOBE NEWSWIRE) — Industrial operations are under pressure from every direction. Energy costs are rising. Legacy systems are holding back progress. The talent pipeline is thinning. And the window to act is narrowing. At Hannover Messe 2026 (20–24 April, Hall 13, Booth C34), Schneider Electric, a global energy technology leader, is showing what it looks like when those problems finally meet their match. Across five live areas — Operational Efficiency, Legacy Drag, the Talent Gap, Data and Cybersecurity, and Energy Efficiency — Schneider Electric, AVEVA, ETAP, and ProLeiT are demonstrating how the convergence of electrification, open software-defined automation, and Industrial AI powered intelligence is already changing the economics...

Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on treatment increased to 19 months  Data highlighted in oral presentation at AACR’s Clinical Trials Mini Symposium Phase 1b indication expansion trial is enrolling SOUTH SAN FRANCISCO, Calif., April 18, 2026 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced the presentation of updated data from its Phase 1 trial of PLN-101095, in combination with pembrolizumab, in patients with immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors. The oral presentation was made at the Clinical Trials Mini Symposium of the American Association for Cancer Research (AACR) 2026 Annual Meeting. Timothy A. Yap, MBBS, Ph.D., Medical Oncologist and Physician-Scientist at the University of Texas...

WUHU, China, April 18, 2026 (GLOBE NEWSWIRE) — Recently, the iCAUR V27 officially obtained the L3 Off-Road Certification from CATARC (China Automotive Technology and Research Center). Based on real-world off-road scenarios, the certification covers extreme conditions such as cross-axle articulation, steep slopes, mud, and gravel roads, with rigorous evaluation standards for off-road capability, four-wheel-drive response, body rigidity, power system stability, and handling reliability. The V27 successfully passed all tests, demonstrating its professional-grade off-road performance. Its previous achievements—crossing the Taklamakan Desert N39 route and the tropical rainforest of Honghe Valley, Yunnan—further validate its stability in complex environments.In off-road recovery, the response speed of four-wheel-drive system is key...

ESCMID: Sanofi’s Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head studyFirst head-to-head, double-blind, randomized phase 4 study powered to directly compare the tolerability profiles of these vaccines in adults in a real-world setting Results were presented today at the European Society of Clinical Microbiology and Infectious Diseases Global Congress in Munich, Germany.Paris, April 18, 2026. Sanofi’s protein-based non-mRNA COVID-19 vaccine Nuvaxovid (NVX-CoV2705) demonstrated statistically significant lower systemic reactogenicity (the expected side effects that might occur following vaccination) compared to mNEXSPIKE (mRNA-1283), Moderna’s latest mRNA COVID-19 vaccine, across all pre-specified endpoints in the COMPARE study. The randomized, double-blind study, which enrolled 1,000...

ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease symptoms in this underserved patient population ADAPT SERON, OCULUS, and Jr study results build on VYVGART’s approved gMG indication and show its potential as the first and only biologic therapy effective across MG subtypes ADHERE post hoc analysis supports earlier use of VYVGART in treatment-naïve CIDP patients, with 87.5% achieving early benefitApril 18, 2026, 7:00 AM CEST Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the presentation of new data for VYVGART® (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa and hyaluronidase-qvfc)...

VANCOUVER, British Columbia, April 17, 2026 (GLOBE NEWSWIRE) — B2Gold Corp. (TSX: BTO, NYSE AMERICAN: BTG, NSX: B2G) (“B2Gold” or the “Company”) announced today that a fire occurred in certain areas of the crushing circuit at the Goose Mine in the evening on April 16, 2026. On-site emergency responders were deployed and immediately initiated response procedures, and the fire was fully extinguished. No injuries were reported, no medical treatment was required, and mining operations are continuing on plan. The Company has been in contact with the relevant regulatory authorities. The Company is investigating the cause of the fire, as well as assessing the damage and potential impact on the operation. The Company’s initial assessment indicates that the fire was localized to the secondary crusher screen and feed belt. Further updates...